Innovative Cancer Detection Lucence specializes in AI-powered liquid biopsy technology for early cancer detection, offering significant potential to expand into healthcare providers seeking cutting-edge diagnostic solutions for improved patient outcomes.

Strategic Collaborations Recent partnerships with Mayo Clinic, NCCS, and DxD Hub demonstrate Lucence’s strong foothold in clinical research and commercial collaborations, providing opportunities to sell integrated diagnostic and research services to leading cancer centers globally.

Expanding Research Footprint Active engagement in multi-million dollar research collaborations like UNITED 2.0 highlights Lucence's commitment to next-generation diagnostics, opening avenues to offer advanced testing platforms and research tools to scientific institutions and biotech partners.

Growing Market Presence With a revenue range of 100 to 250 million and significant funding, Lucence is positioned as a competitive player in the biotech diagnostics space, presenting opportunities to upsell or introduce new liquid biopsy assays to hospitals, labs, and health systems.

Global Expansion Potential Headquartered in Palo Alto and Singapore, and integrating with regional diagnostics networks like Agilus, Lucence’s international footprint presents a compelling opportunity for sales teams to target global markets and enterprise-level healthcare providers seeking innovative cancer diagnostics.